摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-aminobut-2-enoic acid octyl ester | 27618-18-4

中文名称
——
中文别名
——
英文名称
3-aminobut-2-enoic acid octyl ester
英文别名
Octyl 3-amino-2-butenoate;octyl 3-aminobut-2-enoate
3-aminobut-2-enoic acid octyl ester化学式
CAS
27618-18-4
化学式
C12H23NO2
mdl
——
分子量
213.32
InChiKey
VGACEMCIRWAOLF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    317.2±15.0 °C(Predicted)
  • 密度:
    0.938±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    15
  • 可旋转键数:
    9
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    52.3
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    3-aminobut-2-enoic acid octyl ester3-(5,5-二甲基-2-氧代-2-[1,3,2]二氧杂磷杂环己基) -4-(3-硝基苯基)-丁-3-烯-2-酮甲苯 为溶剂, 以36%的产率得到5-(5,5-Dimethyl-2-oxo-2λ5-[1,3,2]dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid octyl ester
    参考文献:
    名称:
    Synthesis of 1,4-Dihydropyridine-5-phosphonates and Their Calcium-Antagonistic and Antihypertensive Activities. Novel Calcium-Antagonist 2-(Benzyl(phenly)amino)ethyl 5-(5,5-Dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate Hydrochloride Ethanol(NZ-105) and Its Crystal Structure.
    摘要:
    研究了3-羧酸酯变体在2,2-二甲基三甲基烯-3-烷氧羰基-4-芳基-1,4-二氢-2,6-二甲基-5-吡啶膦酸酯(1)中与钙拮抗和降压活性相关的影响:合成了含有不超过12个碳的烷基和羧酸酯部分含有氨基功能团的类似物,以检测其生物活性。其中,2-[苄基(苯基)氨基]乙基5-(5,5-二甲基-2-氧-1,3,2-二氧膦杂环己烷-2-基)-1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3-吡啶羧酸酯盐酸盐乙醇(NZ-105)显示出特别有益的活性,并被选中进行进一步的药理学研究和临床开发。描述了通过X射线晶体学分析获得的NZ-105的结构-活性关系和固态结构的一些方面。
    DOI:
    10.1248/cpb.40.2362
  • 作为产物:
    描述:
    乙酰乙酸正辛酯ammonium hydroxide 作用下, 以 乙醇 为溶剂, 反应 14.0h, 以83%的产率得到3-aminobut-2-enoic acid octyl ester
    参考文献:
    名称:
    新型高亲脂性1,4-二氢吡啶的合成与结构研究
    摘要:
    由相应的β-酮制备了一系列新的1,4-二氢吡啶(1,4-DHPs),这些酯在氮环的C3和C5位上带有带有长且官能化的烷氧基链的酯基 酯类依次由脂肪酶催化的酯交换反应制备。结构研究已经由X射线晶体学和在半经验(AM1),从头算 (HF / 6-31G *)和B3LYP / 6-31G *级别的理论计算,发现烷基链对生物活性所需的1,4-DHP几何形状没有任何影响。但是,这些链对亲脂性有很大影响,因此,它们可用于更好地控制药理作用的持续时间。
    DOI:
    10.1039/b506018d
点击查看最新优质反应信息

文献信息

  • Synthesis and Calcium Channel-Modulating Effects of Alkyl (or Cycloalkyl) 1,4-Dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate Racemates and Enantiomers
    作者:Manian Ramesh、Wandikayi C. Matowe、Murthy R. Akula、Dean Vo、Lina Dagnino、Moy Cheong Li-Kwong-Ken、Michael W. Wolowyk、Edward E. Knaus
    DOI:10.1021/jm9704006
    日期:1998.2.1
    that the 2-pyridyl isomers acted as dual cardioselective calcium channel agonists (GPLA)/smooth muscle selective calcium channel antagonists (GPILSM). In contrast, the 3-pyridyl and 4-pyridyl isomers acted as calcium channel agonists on both GPLA and GPILSM. In the C-4 2-pyridyl group of compounds, the size of the C-5 alkyl (or cycloalkyl) ester substituent was a determinant of GPILSM antagonist activity
    一组外消旋烷基(或环烷基)1,4-二氢-2,6-二甲基-3-硝基-4-(2-,3-或4-吡啶基)-5-吡啶羧酸酯异构体(6-14)为使用改进的Hantzsch反应制备的方法,该反应涉及硝基丙酮与3-氨基巴豆酸烷基酯(或环烷基)和2-,3-或4-吡啶甲醛的缩合反应。使用豚鼠回肠纵向平滑肌(GPILSM)和豚鼠左心房(GPLA)分析测定其体外钙通道调节活性,结果表明2-吡啶基异构体可作为双心脏选择性钙通道激动剂(GPLA)/平滑肌选择性钙通道拮抗剂(GPILSM)。相反,3-吡啶基和4-吡啶基异构体在GPLA和GPILSM上均充当钙通道激动剂。在化合物的C-4 2-吡啶基中 C-5烷基(或环烷基)酯取代基的大小是GPILSM拮抗剂活性的决定因素,其中相对活性分布为环戊基和环己基> t-Bu,i-Bu,并且Et> MeOCH2CH2> Me。C-4吡啶基取代基的连接点是GPLA激动剂活性的决定因
  • 1,4-dihydropyridine derivatives
    申请人:FUJIREBIO INC.
    公开号:EP0400660A1
    公开(公告)日:1990-12-05
    1,4-Dihydropyridine derivatives of formula (I): wherein Ar1 and Ar2 each represent an unsubstituted or substituted aromatic hydrocarbon or aromatic heterocyclic group; and R1 represents -C02R2, -SO2R3, -COR4, -CON(R5)2, -CN or -NO2 in which R2 is hydrogen, a straight chain, branched chain or cyclic saturated hydrocarbon group, which may have a substituent or a straight chain, branched chain or cyclic unsaturated hydrocarbon group having 2 to 10 carbon atoms, which may have a substituent, R3 is an alkyl group having 1 to 4 carbon atoms, R4 is an alkyl group having 1 to 4 carbon atoms or a phenyl group; and R5 is an alkyl group having 1 to 4 carbon atoms.
    式(I)的 1,4-二氢吡啶衍生物: 其中 Ar1 和 Ar2 各自代表未取代或取代的芳香烃或芳香杂环基团; 和 R1 代表-C02R2、-SO2R3、-COR4、-CON(R5)2、-CN 或 -NO2,其中 R2 是氢、直链、支链或环状饱和烃基(可有取代基)或具有 2 至 10 个碳原子的直链、支链或环状不饱和烃基(可有取代基),R3 是具有 1 至 4 个碳原子的烷基,R4 是具有 1 至 4 个碳原子的烷基或苯基; R5 是具有 1 至 4 个碳原子的烷基。
  • Synthesis and antihypertensive activity evaluation in spontaneously hypertensive rats of nitrendipine analogues
    作者:Kai Zhou、Xiao-meng Wang、Yi-zhi Zhao、Yong-xiao Cao、Qiang Fu、San-qi Zhang
    DOI:10.1007/s00044-010-9477-0
    日期:2011.11
    The antihypertensive activity of nitrendipine analogues can be improved by properly lengthening its alkyl chain in 3- or 5-position. Nitrendipine and its seven analogues were synthesized, and their antihypertensive activities in spontaneously hypertensive rats (SHR) were evaluated by ig administration. It was found that 5-n-heptyl 3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate [(+/-)-5] exhibited the strongest antihypertensive effect amongst eight compounds. (+)-5-n-heptyl 3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate [(+)-5] was also prepared. Antihypertensive activities of (+/-)-5 and (+)-5 in SHR were compared. The results showed that (+/-)-5 and (+)-5 had a higher potency than nitrendipine, and (+)-isomer was 1.79-fold the raceme at a dose of 2 mg/kg.
  • US4622332A
    申请人:——
    公开号:US4622332A
    公开(公告)日:1986-11-11
  • US5276150A
    申请人:——
    公开号:US5276150A
    公开(公告)日:1994-01-04
查看更多